STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy, safety and tolerability of once-monthly
administration of intravenous Mircera for the maintenance of hemoglobin levels in dialysis
participants with chronic renal anemia. Participants will receive monthly intravenous
injections of Mircera, at a starting dose of 120, 200 or 360 micrograms, according to the
dose of epoetin administered in the week preceding first study drug administration. The
anticipated time on study treatment is 3-12 months, and the target sample size is 100-500
individuals.